替普利珠单抗治疗2期1型糖尿病的真实世界代谢与免疫评估
该研究在美国FDA批准替普利珠单抗后,首次在真实世界中对2期1型糖尿病患者进行前瞻性观察,比较治疗组(n=30)与未治疗组(n=10)的代谢和免疫指标。结果显示治疗组在2-6个月随访时OGTT 2小时血糖和HbA1c显著改善,且CD4前胰岛素特异性TCR下降与C肽AUC较高相关,提示免疫变化可能作为早期干预的生物标志物。
要点
- 替普利珠单抗在真实世界临床实践中可安全有效地给药。
- 治疗组2-6个月随访时OGTT 2小时血糖和HbA1c显著改善。
- CD4前胰岛素特异性TCR下降与较高C肽AUC相关,或为生物标志物。
核心结论
- 替普利珠单抗在临床实践中可安全有效地使用,早期血糖改善和CD4前胰岛素特异性TCR减少提示治疗后免疫变化或可指导早期干预。
研究设计与样本
- 这是一项在美国FDA批准替普利珠单抗后开展的真实世界前瞻性观察研究,在Barbara Davis中心早期1型糖尿病门诊前瞻性随访2期1型糖尿病儿童和成人。
- 治疗组为2023年4月至2025年2月期间接受替普利珠单抗的个体(n=30),对照组为未治疗个体(n=10)。
- 关键评估包括OGTT、HbA1c和CGM数据,于治疗前后收集;纵向代谢数据最多涵盖22名治疗参与者,随访在治疗后2至13个月进行。
- 通过基于PCR的靶向TCR测序检测EBV和胰岛抗原靶向TCRβ链的纵向变化。
主要发现
- 在治疗后2至6个月随访的治疗个体中,OGTT 2小时血糖从10.7 ± 2.1 mmol/l改善至8.8 ± 2.8 mmol/l(p=0.007)。
- HbA1c从40 ± 4 mmol/mol(5.8 ± 0.4%)改善至39 ± 6 mmol/mol(5.7 ± 0.5%)(p=0.044)。
- 67%的个体CGM时间≥7.8 mmol/l保持稳定或减少。
- 治疗后CD4前胰岛素特异性TCR下降,而未治疗组无变化;这些下降与较高的C肽AUC相关(r=-0.656,p=0.013)。
- 替普利珠单抗治疗前后EBV TCR序列相似。
临床怎么用
- 在2期1型糖尿病患者中,可考虑使用替普利珠单抗以改善早期血糖指标。
- CD4前胰岛素特异性TCR变化或可作为监测治疗反应的生物标志物,辅助早期干预决策。
局限性
- 样本量较小(治疗组n=30,对照组n=10),纵向代谢数据仅部分参与者可用。
- 为观察性研究,非随机对照,可能存在混杂因素。
- 随访时间较短(2至13个月),长期结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This is the first real-world prospective observational study of teplizumab use following approval by the United States Food and Drug Administration in individuals with stage 2 type 1 diabetes. We examined whether glycaemic responses observed in controlled trials were reproduced in real-world practice and explored immunological biomarkers associated with treatment. METHODS: Children and adults with stage 2 type 1 diabetes were prospectively followed in the Early Type 1 Diabetes Clinic at the Barbara Davis Center. Individuals who received teplizumab between April 2023 and February 2025 (n=30) were compared with an untreated group (n=10). Key assessments included OGTTs, HbA1c measurements and continuous glucose monitoring (CGM) data, collected before and after treatment. Longitudinal metabolic data were available for up to 22 treated participants, with follow-up assessments occurring between 2 and 13 months after treatment. Changes in Epstein-Barr virus (EBV) and islet antigen-targeting T cell receptor (TCR) β chains were measured longitudinally from genomic DNA via a PCR-based targeted TCR sequencing assay. RESULTS: Among treated individuals followed up between 2 and 6 months after treatment, OGTT 2 h glucose improved (10.7 ± 2.1 to 8.8 ± 2.8 mmol/l, p=0.007), as did HbA1c (40 ± 4 to 39 ± 6 mmol/mol [5.8 ± 0.4% to 5.7 ± 0.5%], p=0.044). In addition, 67% had a stable or reduced CGM time ≥7.8 mmol/l. CD4 preproinsulin-specific TCRs declined after treatment, with no change in the untreated group. These reductions correlated with higher C-peptide AUC (r=-0.656, p=0.013). EBV TCR sequences were similar before and after teplizumab treatment. CONCLUSIONS/INTERPRETATION: Teplizumab can be safely and effectively administered in clinical practice. Early glycaemic improvements and reductions in CD4 preproinsulin-specific TCRs suggest that post-treatment immunological changes may serve as biomarkers to guide early-stage intervention.
引用
- Karakus KE, Chesshir L, Walker S, et al. Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes. Diabetologia. 2026. PMID: 41535597. doi:10.1007/s00125-025-06646-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。